Health Condition 1: I509- Heart failure, unspecified
Conditions
Interventions
Intervention1: Nil: Nil
Intervention2: Nil: Nil
Intervention3: Nil: Nil
Sponsors
DrKRaaga Meghana
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients diagnosed with both heart failure and type 2 diabetes mellitus 2. Patients aged 18 years or above 3. Patients willing to provide informed consent 4. Patients able to comply with follow-up visits 5. For Dapa (+) group: Patients already on dapagliflozin 10 mg once daily as part of their treatment regimen 6. For Dapa (-) group: Patients not receiving any SGLT2 inhibitor
Exclusion criteria
Exclusion criteria: 1. Patients with type 1 diabetes mellitus 2. Patients with severe renal impairment (eGFR less than 30mL per min) 3. Patients with documented hypersensitivity or contraindications to dapagliflozin 4. Patients with acute coronary syndrome within the past 3 months 5. Pregnant or lactating women 6. Patients with malignancy or life-threatening conditions 7. Patients unwilling to provide informed consent 8. Patients unable to comply with follow-up requirements
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine association between dapagliflozin, cardiac bio markers and cardiac remodeling in patients with heart failure and type 2 diabetes mellitus.Timepoint: 6months and 12 months | — |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate the risk of developing heart failure in diabetic patients.Timepoint: 1 year | — |
Countries
India
Contacts
Public ContactDinesh Patil
Dr D Y Patil medical college
Outcome results
None listed